Supreme Court’s Wyeth v. Levine Ruling Returns Industry To Status Quo On Pre-Emption
This article was originally published in The Pink Sheet Daily
Executive Summary
The court finds that FDA-approved labeling does not pre-empt individuals from bringing product liability suits under state law.
You may also be interested in...
Zohydro v. Massachusetts = Wyeth v. Levine? State Asserts Power To Seek Label Change
Arguing for its right to ban Zogenix Inc.’s opioid, Massachusetts contends that FDA clearance of a drug for marketing is a “gateway approval” that does not preempt states from imposing stricter requirements on a product.
Takeda False Claim Act Case May Allow Supreme Court To Set Evidence Threshold
High court seeks Solicitor General’s views on whether a whistleblower must identify a specific false claim submitted to the government or just have evidence to infer the submission; Solicitor General has previously supported latter position.
Generic Liability: Supreme Court Appears Divided On Whether ANDA Sponsors Must Seek Label Change When New Risks Emerge
In oral arguments in Pliva v. Mensing, justices suggest generic companies have an obligation to ask FDA to revise labeling; Chief Justice John Roberts Jr. says that could lead to boilerplate letters to FDA.